Medicago and GSK Report Results of Plant-Derived Vaccine in a P-II Study for COVID-19

 Medicago and GSK Report Results of Plant-Derived Vaccine in a P-II Study for COVID-19

Medicago and GSK Report Results of Plant-Derived Vaccine in a P-II Study for COVID-19

Shots:

  • The P-II study involves assessing the safety & immunogenicity of the CoVLP vs PBO in 306 subjects aged ≥18yrs. with two age groups (18-64yrs & over 65yrs.) across the US & Canada
  • Results: vaccine induced humoral immune response of similar strength in both age cohorts after two doses, both age cohorts responded with NAb titers that were about 10 times higher than those in a panel of sera from patients recovering from COVID-19, well tolerated with acceptable safety profile
  • CoVLP has received the US FDA’s FTD while Health Canada has initiated a review of Medicago’s COVID-19 rolling submission under the interim order

Click here to­ read full press release/ article | Ref: GSK | Image: Bloomberg Quint

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post